165 related articles for article (PubMed ID: 15850720)
1. Fluvastatin plus fish oil are more effective on cardiovascular risk factors than fluvastatin alone.
Singer P
Prostaglandins Leukot Essent Fatty Acids; 2005 May; 72(5):379-80. PubMed ID: 15850720
[No Abstract] [Full Text] [Related]
2. Does time of onset of therapy alter the protective cardiovascular effect of fluvastatin after renal transplantation?
Morales JM
Nat Clin Pract Nephrol; 2005 Dec; 1(2):78-9. PubMed ID: 16932372
[No Abstract] [Full Text] [Related]
3. Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Corsini A; Holdaas H
Ren Fail; 2005; 27(3):259-73. PubMed ID: 15957541
[TBL] [Abstract][Full Text] [Related]
4. Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IV study.
Schouten O; Poldermans D; Visser L; Kertai MD; Klein J; van Urk H; Simoons ML; van de Ven LL; Vermeulen M; Bax JJ; Lameris TW; Boersma E
Am Heart J; 2004 Dec; 148(6):1047-52. PubMed ID: 15632892
[No Abstract] [Full Text] [Related]
5. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE-IV).
Dunkelgrun M; Boersma E; Schouten O; Koopman-van Gemert AW; van Poorten F; Bax JJ; Thomson IR; Poldermans D;
Ann Surg; 2009 Jun; 249(6):921-6. PubMed ID: 19474688
[TBL] [Abstract][Full Text] [Related]
6. Fluvastatin: what is the evidence?
Bagg W; Braatvedt G
N Z Med J; 1997 Aug; 110(1050):321-2. PubMed ID: 9315035
[No Abstract] [Full Text] [Related]
7. Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials.
Winkler K; Ablethauser CB; Gimpelewicz C; Bortolini M; Isaacsohn JL
Clin Ther; 2007 Sep; 29(9):1987-2000. PubMed ID: 18035198
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of hypercholesterolemia in kidney transplant recipients].
Fritsche L; Budde K; Neumayer HH
Dtsch Med Wochenschr; 2003 Apr; 128(16):879-81. PubMed ID: 12701034
[No Abstract] [Full Text] [Related]
9. [High therapeutic effect and safety of fluvastatin].
Pharm Unserer Zeit; 2003; 32(6):516-7. PubMed ID: 14639833
[No Abstract] [Full Text] [Related]
10. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients.
Kasiske BL;
Am J Transplant; 2005 Jun; 5(6):1576. PubMed ID: 15888073
[No Abstract] [Full Text] [Related]
11. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: lessons to be learnt from the assessment of Lescol in renal transplantation (ALERT) trial.
Holdaas H; Fellström B; Jardine AG;
Am J Transplant; 2005 Jun; 5(6):1574-5. PubMed ID: 15888072
[No Abstract] [Full Text] [Related]
12. Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers.
Yasue H; Mizuno Y; Harada E; Itoh T; Nakagawa H; Nakayama M; Ogawa H; Tayama S; Honda T; Hokimoto S; Ohshima S; Hokamura Y; Kugiyama K; Horie M; Yoshimura M; Harada M; Uemura S; Saito Y;
J Am Coll Cardiol; 2008 May; 51(18):1742-8. PubMed ID: 18452779
[TBL] [Abstract][Full Text] [Related]
13. The use of fluvastatin in cardiovascular risk management.
McDonald KJ; Jardine AG
Expert Opin Pharmacother; 2008 Jun; 9(8):1407-14. PubMed ID: 18473714
[TBL] [Abstract][Full Text] [Related]
14. [Not just decreased LDL level is decisive. Which statin for patients at risk for coronary disease?].
MMW Fortschr Med; 2004 Jun; 146(24):1-3. PubMed ID: 15366507
[No Abstract] [Full Text] [Related]
15. Fluvastatin increases LDL particle size and reduces oxidative stress in patients with hyperlipidemia.
Yoshino G; Hirano T; Kazumi T; Takemoto M; Ohashi N
J Atheroscler Thromb; 2003; 10(6):343-7. PubMed ID: 15037823
[TBL] [Abstract][Full Text] [Related]
16. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials.
Holdaas H; Wanner C; Abletshauser C; Gimpelewicz C; Isaacsohn J
Int J Cardiol; 2007 Apr; 117(1):64-74. PubMed ID: 16889855
[TBL] [Abstract][Full Text] [Related]
17. Management of dyslipidemia in renal disease and transplantation.
Zolezzi M
Saudi J Kidney Dis Transpl; 2006 Jun; 17(2):129-36. PubMed ID: 16903617
[No Abstract] [Full Text] [Related]
18. Fluvastatin as co-medication in heart transplant recipients with elevated creatine-kinase.
Sadoni S; Kaczmarek I; Delgado O; Schmöckel M; Reichart B; Meiser B
Transplant Proc; 2007 Mar; 39(2):558-9. PubMed ID: 17362781
[TBL] [Abstract][Full Text] [Related]
19. Statin + fibrate combination therapy--fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease.
Wray R; Hemsley D
Int J Cardiol; 1999 Dec; 71(3):291. PubMed ID: 10636539
[No Abstract] [Full Text] [Related]
20. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
